Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series.
Conclusion: Post-transplantation treatment of chronic HCV is preferred in KTRs. The sofosbuvir/daclatasvir regimen as an interferon-free therapy is a safe, effective option for HCV infection in pediatric KTRs, who can tolerate sofosbuvir/daclatasvir well and respond favorably without significant adverse events. PMID: 32606888 [PubMed]
Conclusion: Certain components of online reviews are significantly correlated with ICH-CAHPS measures of patient experience. Additionally, online reviews come with narrative comments that can offer specific insights into positive and negative aspects of patient care that cannot always be elucidated by numeric survey questions. Online reviews may have utility as an adjunctive source of information to patient experience surveys such as the ICH-CAHPS.
Prog Brain Res. 2021;265:231-247. doi: 10.1016/bs.pbr.2021.06.006. Epub 2021 Aug 13.ABSTRACTClinical neurorestorative cell therapies for stroke have been explored for over 20 years. Majority cell therapies have shown neurorestorative effects for stroke on non-double-blind studies. In this review, we summarize types of cell transplantation, transplanted routes, therapeutic time windows, dosage, results of exploring trials or clinical studies, results of multicenter, double-blind or observing-blind, randomized, placebo-controlled clinical trials. The clinical application prospects of majority cell therapies for stroke need t...
Curr Opin Organ Transplant. 2021 Sep 24. doi: 10.1097/MOT.0000000000000923. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Transplantation continues to be the only treatment option for end-stage organ failure when other interventions have failed. Although short-term outcomes have improved due to advances in perioperative care, long-term outcomes continue to be adversely affected by chronic rejection. Little is known about the role microbiota play in modulating alloimmune responses and potentially contributing to graft failure. Initial data have identified a correlation between specific changes of the recipient and/or don...
No abstract available
TP53 gene mutations are common in myelodysplastic syndromes (MDS). Previous studies have reported their detrimental effects on patient survival. However, current treatment strategies mainly based on hypomethylating agent therapy(HMA) and hematopoietic stem cell transplantation(HSCT) still leave a lot to be desired. And there is also a lack of studies on large sample with a view to the refinement of specific characteristics and disease progression. So we performed a meta-analysis including 20 studies compromising 5067 patients to assess the prognostic impact and clinical characteristics of TP53 mutations in MDS patients.
Inter-individual variability in tacrolimus exposure is substantial and caused by multiple patient characteristics, including concomitant medications and CYP3A5 genotype/phenotype. CYP3A5 phenotype is determined by common genetic variation in the CYP3A5 gene. Patients carrying at least one copy of the wild-type, CYP3A5*1 allele are CYP3A5 expressers and have an active CYP3A5 enzyme. Patients carrying two no-function copies of the gene (e.g. CYP3A5*3 or CYP3A5*6 alleles) have no active CYP3A5 enzyme.
Methamphetamine use in adults aged 18 to 64 years increased 43% between 2015 and 2019, astudy in JAMA Psychiatry has found. The study also found that overdose deaths involving psychostimulants other than cocaine, mostly methamphetamine, increased 180% during the same period.Beth Han, M.D., Ph.D., M.P.H., of the National Institute on Drug Abuse (NIDA) and colleagues examined data from 195,711 people who responded to the annual National Survey on Drug Use and Health (NSDUH) between 2015 and 2019. The NSDUH, published by the Substance Abuse and Mental Health Services Administration, is a comprehensive survey of approximately ...
We describe a successfully diagnosed and treated CHL-PTLD stage IV pediatric patient, 8 years after liver transplantation. The patient was treated with standard CHL (Children’s Cancer Group 5942 group 3) chemotherapy, rituximab and reduction of immunosuppressant. The patient remains in complete remission after 3 years with stable graft function. To our best knowledge, this is the first pediatric case report of a successfully treated stage IV CHL-PTLD after a liver transplant.
Conclusions: In Argentina, we did not show significant differences in outcomes between MSD and MUD HSCT for children with high-risk leukemia. Future work should focus on strategies to reduce the relapse risk in children with high-risk leukemia in upper-middle-income countries.